123 related articles for article (PubMed ID: 37328387)
1. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer.
Nagai M; Nakamura K; Terai T; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
Pancreatology; 2023 Sep; 23(6):721-728. PubMed ID: 37328387
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5792-5800. PubMed ID: 37248377
[TBL] [Abstract][Full Text] [Related]
3. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Usefulness in Patients with Normal CA19-9.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5801-5802. PubMed ID: 37355518
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
7. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery.
Li X; Liu X; Lu N; Chen Y; Zhang X; Guo C; Xiao W; Xue X; Sun K; Wang M; Gao S; Shen Y; Zhang M; Wu J; Que R; Yu J; Bai X; Liang T
BMC Cancer; 2023 Jan; 23(1):49. PubMed ID: 36641427
[TBL] [Abstract][Full Text] [Related]
8. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer.
Sunagawa Y; Yamada S; Sato Y; Morimoto D; Sonohara F; Takami H; Inokawa Y; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Ann Surg Oncol; 2020 Jun; 27(6):2081-2089. PubMed ID: 31673938
[TBL] [Abstract][Full Text] [Related]
9. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
12. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
[TBL] [Abstract][Full Text] [Related]
13. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Ide Y; Otsuka T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Shinohara Y; Ueno S; Taguchi H; Honda T; Shibuki T; Nio K; Ureshino N; Mizuta T; Mitsugi K; Shirakawa T
Anticancer Res; 2023 Apr; 43(4):1817-1826. PubMed ID: 36974805
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
15. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
17. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
[TBL] [Abstract][Full Text] [Related]
18. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment.
Asano T; Hirano S; Nakamura T; Okamura K; Tsuchikawa T; Noji T; Nakanishi Y; Tanaka K; Shichinohe T
J Hepatobiliary Pancreat Sci; 2018 Jul; 25(7):342-350. PubMed ID: 29797499
[TBL] [Abstract][Full Text] [Related]
20. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
